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The fibrolamellar variant of hepatocellular carcinoma (HCC) is an uncommon tumour with
distinctive clinical and histological features. Although the first case of fibrolamellar hepato-
cellular carcinoma (FI-HCC) was described by Edmondson in 1956, and later confirmed in five
patients by Peters, the majority of reports followed those of Berman et al. and Craig et al. .2.
A case ofFI-HCC, which is rarely diagnosed in Mediterranean countries including Turkey,
is presented in the following report.
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CASE REPORT
A 21-year-old male without a history of chronic alco-
hol abuse and cirrhosis presented in April 1989, with a
one month history of right upper abdominal pain and
a mass, this was diagnosed as a liver abccess and
operated on in an urban hospital. A large mass in the
right lobe ofthe liver was found and only a biopsy was
performed. Histological examination revealed HCC.
Almost one year later, while he was doing his military
service, this patient was admitted to our hospital
because of right upper abdominal pain and a mass.
Physical examination was unremarkable except for
hepatomegaly (liver edge 5 cm. below the right costal
margin) and in particular there were no stigma of
chronic liver disease. His liver function tests were
normal: alkaline phosphatase (AP) 258 /L, aspartate
transaminase 34 Q/L, bilirubin (total and direct) 0.4
and 0.1 g/L, with a normal albumin (3.3 g/l) and pro-
trombin time (13 second). Viral serology, hepatitis B
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surface antigen (HBsAg) were all negative and tumor
markers includingAFP (3.2 ng/ml) and carcinoembri-
onic antigen (CEA) (3.1 ng/ml) were normal. Only
ferritin was moderately elevated (320 ng/ml). Ultra-
sound revealed a hypoechoic mass. Abdominal com-
puted tomography scan (ACTS) revealed a well-cir-
cumscribed, hypodense, large mass (13 x 10 x 11 cm.)
with some necrotic areas, in the right lobe of the liver
(Fig. 1). Since these findings and patient’s history were
not typical of HCC, biopsy specimens which were
taken at the first operation were reevaluated at our
hospital and the findings supported FI-HCC.
A right hepatic lobectomy and cholecystectomy
were performed using the finger fracture method in
May 1990. The gross specimen demonstrated a well-
circumscribed, moderately firm, gray-white, 13 x 10 x
7 cm. lobulated mass with a fine central stellate fibrous
scar and septa radiating to the periphery (Fig. 2). The
remainder of the liver was noncirrhotic and grossly
unremarkable. No metastasis or lymph nodes were
identified at operation. Histological examination of
the tumor revealed the characteristic appearance of
FI-HCC, with large polygonal cells lying within a
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Figure 1 CT scan showing a tumour mass in right site of the liver. Figure 4 PostoperativeCT scan shows only hypertrophy of left side
of the liver.
lamellar fibrous stroma (Fig. 3). The cells had eosi-
nophillic cytoplasm, some with pale inclusions. With
CEA stain CEA positive tumor cells were not found,
only bile ducts showed a positive reaction. Follow up
at 27 months failed to show recurrence of the tumor.
In this last evaluation, ACTS revealed only hyper-
trophy of left lobe ofiiver (Fig. 4). Bone scintigraphy,
routine biochemical and.hematological values (includ-
ing blood ferritin level) were all normal.
Figure2 Gross specimendemonstratesa lobulatedmasswithawhite
central stellate scar. See Color Plate I.
Figure 3 Large polygonal cells are traversed by bands of fibrous
tissue with a lamellar pattern (hemotoxylin and eosin stain x 100).
DISCUSSION
HCC is a disease ofwidely varying epidemiology. It is
relatively uncommon among adults in North America
and Europe, where it is usually a disease of cirrhotic
males aged 50 to 70 years. It is relatively more
common in the Orient, Saudi Arabia and particularly
in subsaharan Africa. Nevertheless, the majory of the
FI-HCC have been reported from USA and especially
there are very few cases reported from Mediterranean
Countries.
The literature reveals that FI-HCC is a distinct
clinical entity with a mean age of 23, less than 10
percent of the patients over 35 years of age and an
almost equal sex ratio4,5. Patients with FI-HCC are
more likely to have abdominal pain and a palpable
abdominal mass or hepatomegaly. Sometimes, jaun-
dice, phlebitis, hemoperitoneum or gynaecomastia
may be seen4. By contrast with HCC, only 5 to 10
percent of patients with FI-HCC are positive for
HBsAg and 10 to 14 percent have modest elevations of
AFP levels. The diminished expression of AFP, an
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concept of FI-HCC being a better differentiated
tumor4,5,6. Serum unsaturated vitamin B12 binding
capacity and plasma neurotensin level may be used to
monitor the regression or recurrence of the tumor
postoperatively5. Another reported parameter which is
elevated in FI-HCC, is ferritin. However, ferritin has
been reported to be elevated in not only cases ofHCC
but also some other neoplastic disease such as breast
and lung cancers, neuroblastoma, multiple myelomas.
FI-HCC is usually a large, firm, grey solitary mass
at the time ofpresentation, in contrast to HCC; which
is often multiple, soft and hemorrhagic. FI-HCC
frequently appears in a noncirrhotic liver as a well
circumscribed mass with a central stellate scar and
prominent fibrous tissue, reminiscent of focal nodular
hyperplasia (FNH). A possible relationship of FI-
HCC to FNH has been speculated 1,3. Some authors
have attempted to link FNH with FI-HCC suggesting
that the latter may represent the malignant counter-
part of the former6. This was based or their macro-
scopic similarities, their common age and gender, and
the presence ofFNH adjacent to FI-HCC in some of
the early reports ofFI-HCC. However, lots of studies
revealed that only 5% of cases of FI-HCC had FNH
identified in the same liver, providing little support for
such an association.
The histologic criteria for FI-HCC are well defined
and the diagnosis can be readily made by the identi-
fication of the characteristic large oncocytic tumor
cells embedded within lamellar fibrosis. Since the first
descriptions of FI-HCC, the presence of hyaline
globules, focal ground glass cytoplasmic changes and
intracytoplasmic "pale bodies" have been prominently
described1,2,4. Our case is a typical sample of FI-HCC
with this macroscopic and microscopic appearance.
The FI-HCC reported in the literature have a high
resectabilty rate (48-100%) ,,3,4,s, where as, the resect-
abilty rate of patients with HCC is 10 to 23%2’7. The 5
year survival rate of the patients with FI-HCC who
had complete tumor resection was 45 to 56%, with a
median survival time of 50 to 68 months,3,s. The 5 year
survival of patients with HCC who had complete
tumor resection was 0 percent, with median survival
time 7-22 months2. The noncirrhotic fibrolamellar
patients had significantly longer median survival than
noncirrhotic hepatocellular carridone patients. Also
fibrolamellar patients with solitary tumors survived
twice as long as those with multiple lesions7. Although
some authors have argued that patients with FI-HCC
are ideal candidates for liver transplantation, resection
appears to be an effective therapeutic modality3,4,,6.
In a conclusion, FI-HCC, seems to be a distinct
clinical entity that mainly occurs in young patients.
The prognosis in patients treated with a curative resec-
tion is good.
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